VAMG
VRDN icon

Voisard Asset Management Group’s Viridian Therapeutics VRDN Stock Holding History

Voisard Asset Management Group’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-100
Closed -$2.27K – 643
2024
Q3 		$2.27K Hold
100
– – ﹤0.01% 382
2024
Q2 		$1.3K Hold
100
– – ﹤0.01% 342
2024
Q1 		$1.75K Hold
100
– – ﹤0.01% 307
2023
Q4 		$2.18K Buy
+100
New +$1.58K ﹤0.01% 319

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return

Voisard Asset Management Group's VRDN Position: Q4 2024 in Review

Voisard Asset Management Group sold out of Viridian Therapeutics (VRDN) in Q4 2024, closing a stake of 100 shares — an estimated $2.27K sold.

Voisard Asset Management Group first reported a position in VRDN in Q4 2023 and held it in 4 quarters. The position peaked at $2.27K in Q3 2024. 178 funds tracked by Wall St. Rank hold VRDN as of Q4 2024.

  • Voisard Asset Management Group reported no remaining Viridian Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Voisard Asset Management Group sold 100 Viridian Therapeutics shares in Q4 2024, an estimated $2.27K.
  • Voisard Asset Management Group first reported a position in Viridian Therapeutics in Q4 2023 and held it in 4 quarters.
  • Voisard Asset Management Group's Viridian Therapeutics position peaked at $2.27K in Q3 2024.
  • 178 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q4 2024.

Based on Voisard Asset Management Group's 13F filing for Q4 2024, filed 7 Feb 2025.